US Stock Volatility: Johnson & Johnson Plunges on October 13 Due to Pressure on Medical Device Business and Talcum Powder Lawsuit Costs

Johnson & Johnson October 13 Drop Explained

Keywords: Pressure on device business, talcum powder litigation costs

1. The third-quarter results announced on October 13 showed that several segments of the medical technology business underperformed expectations, with overall operational growth at 6%, below analysts' expectations of 7.4%; surgical revenue declined and the performance of the medical device business dragged down overall results.

2. The results announced on October 13 included a one-time charge related to the proposed resolution of talcum powder litigation, causing third-quarter diluted earnings per share to fall to $0.09, a significant year-on-year decline; although adjusted earnings per share beat expectations and full-year guidance was raised, reported profit remains under clear pressure.

(Disclaimer: This content is generated by AI technology based on publicly available information for reference only and does not constitute investment advice.)